Medical Management of Benign Prostatic Hyperplasia (BPH)

BPH causes lower urinary tract symptoms (LUTS) through bladder outlet obstruction (static component - glandular enlargement) and increased smooth muscle tone (dynamic component - alpha-adrenergic mediated). Medical therapy targets these two mechanisms, plus bladder dysfunction from long-standing obstruction. Indicated for moderate-to-severe LUTS (IPSS ≥8) without absolute indications for surgery (refractory retention, recurrent UTI/hematuria, renal insufficiency, bladder stones).

1. Alpha-1 Adrenergic Blockers (first-line)

Relax prostatic and bladder neck smooth muscle, reducing the dynamic component of obstruction. Onset of symptom relief is fast (days).

Tamsulosin, alfuzosin, silodosin - relatively uroselective (alpha-1A/1D), less orthostatic hypotension; silodosin has the highest rate of ejaculatory dysfunction.
Doxazosin, terazosin - non-selective, require dose titration, more hypotension/dizziness, useful if patient also has hypertension.
Efficacy among agents is roughly equivalent; drug choice depends on side-effect profile - Campbell-Walsh Urology notes ejaculatory dysfunction risk is drug-dependent (higher with silodosin/tamsulosin than alfuzosin).
Caution: intraoperative floppy iris syndrome during cataract surgery - alert ophthalmologist before starting.

2. 5-alpha-Reductase Inhibitors (5-ARIs)

Block conversion of testosterone to dihydrotestosterone (DHT), shrinking glandular (epithelial) tissue over months.

Finasteride (blocks type 2 isoenzyme) and dutasteride (blocks type 1 and 2) reduce prostate volume by ~20-30% and PSA by ~50% over 6-12 months.
Best suited for larger prostates (generally >30-40 g) - the Campbell-Walsh data cited in the library show dutasteride monotherapy was superior to tamsulosin for long-term symptom relief and reduced risk of acute urinary retention and need for surgery in larger glands.
Slower onset (3-6 months); reduce long-term risk of progression, retention, and BPH-related surgery.
Side effects: erectile/ejaculatory dysfunction, decreased libido, gynecomastia; must halve measured PSA when interpreting values for prostate cancer screening.

3. Combination Therapy (alpha-blocker + 5-ARI)

The MTOPS and CombAT (dutasteride + tamsulosin) trials, referenced in Campbell-Walsh Urology, demonstrated combination therapy is superior to either monotherapy for reducing symptom progression, acute urinary retention, and need for surgery, particularly in men with larger prostates (>30-40 mL) and higher PSA.
Recommended for men with moderate-severe LUTS plus an enlarged, high-risk prostate expected to progress.

4. Phosphodiesterase-5 Inhibitors (PDE5i)

Tadalafil 5 mg daily is FDA-approved for LUTS/BPH (approved 2011, per Campbell-Walsh), including in men with concurrent erectile dysfunction.
Improves smooth muscle relaxation in the prostate/bladder neck and detrusor via nitric oxide-cGMP pathway.
Can be combined with alpha-blockers (studied with tamsulosin) though caution is needed regarding additive hypotension.
Useful option when ED coexists with LUTS.

5. Antimuscarinics / Beta-3 Agonists (for storage-predominant symptoms)

If storage symptoms (urgency, frequency, urge incontinence) predominate over voiding symptoms and post-void residual is low, antimuscarinics (e.g., oxybutynin, tolterodine, solifenacin) or the beta-3 agonist mibegron can be added to an alpha-blocker.
Requires exclusion of significant residual urine/retention risk before use, since these agents can worsen retention.

6. Combination Approaches Summary

Symptom Profile	Preferred Regimen
Mild-moderate LUTS, smaller prostate	Alpha-blocker monotherapy
Larger prostate, elevated PSA, progression risk	5-ARI or alpha-blocker + 5-ARI combo
LUTS + erectile dysfunction	Tadalafil 5 mg daily (± alpha-blocker)
LUTS with storage symptoms/overactive bladder	Alpha-blocker + antimuscarinic or beta-3 agonist

Monitoring and Escalation

Patients are followed with symptom scores (IPSS), uroflowmetry, and post-void residual. Failure of medical therapy, or development of absolute surgical indications (refractory urinary retention, recurrent UTIs, bladder stones, gross hematuria, renal insufficiency from obstruction), warrants referral for surgical/minimally invasive management (TURP, HoLEP, UroLift, Rezum, simple prostatectomy, etc.).

Sources: Campbell-Walsh Wein Urology (3-volume set); Goldman-Cecil Medicine; Sabiston Textbook of Surgery.

Recent Evidence Note

A 2024 systematic review/network meta-analysis (PMID: 38600763) evaluated re-intervention rates of newer surgical interventions for BPH, and a 2024 systematic review (PMID: 38656693) assessed minimally invasive surgical therapies in geriatric patients - relevant if medical therapy fails and surgery is being considered, but doesn't change first-line medical management above. Also worth flagging: the AUA is releasing an updated BPH/LUTS Guideline (2026) with a dedicated "Part II: Medical Management" section (currently indexed on PubMed, PMID 42095477) - this may refine recommendations on drug selection and combination therapy sequencing beyond what's summarized here. If precise, guideline-level dosing or updated recommendation grades are needed, I'd recommend checking that guideline directly once fully published, as it postdates my textbook sources.

This is a shared conversation. Sign in to Orris to start your own chat.